PT-141 (Bremelanotide)

10mg · Lyophilized Powder · 1,025.2 Da

$85.00 CAD

PT-141 (Bremelanotide) is a cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) developed from Melanotan II research, FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi. Unlike PDE5 inhibitors that work through vascular mechanisms, PT-141 acts centrally by activating melanocortin receptors in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area.

Research Applications

•Central MC3R/MC4R activation for sexual arousal and desire research

•Central nervous system dopaminergic pathway research (reward/arousal)

•Female hypoactive sexual desire disorder (HSDD) research

•Male sexual dysfunction research via non-vascular central mechanism

•Melanocortin receptor agonism and appetite/arousal intersection research

•Comparative research versus PDE5-inhibitor pathways

VIAL10 mg

PURITY≥99% (HPLC)

FORMLyophilized powder

STORAGE-20°C lyophilized / 2-8°C reconstituted

RECON3.0 mL BAC water

USEResearch only

VIEW DOSING PROTOCOL →

All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.